Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VCI-002
- Development stage
- Preclinical
- Lead developer
- Vinci
- Modality
- Small Molecules
- Administration
- Implant, Ophthalmic
01
Overview
VCI-002 (EPIPLANT) is a preclinical-stage drug-device combination product being developed by Vinci Pharmaceuticals for the treatment of retinal diseases, including diabetic macular edema (DME) and intermediate age-related macular degeneration (AMD). Licensed from the Retina Foundation of the Southwest, the technology consists of a bioerodible episcleral implant designed to be placed on the outer surface of the eye. This platform provides sustained, needle-free drug delivery of small molecule active ingredients directly to retinal tissues, specifically targeting the macula, to reduce the treatment burden associated with frequent intravitreal injections. Vinci Pharmaceuticals plans to initiate a Phase 1/2a first-in-human clinical study for VCI-002 in 2027.
- Brand names
- EPIPLANT
- Other names
- EPIPLANT VCI-002
Beyond the preview
Go deeper on VCI-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VCI-002.